Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

PURPOSE: To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2−) breast cancer, with deleterious or suspected deleterious germline BRCA1/2 mutations (gBRCA1/2 m). METHODS: In this open-label, phase II,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Sun, Tao, Shi, Yanxia, Cui, Jiuwei, Yin, Yongmei, Ouyang, Quchang, Liu, Qiang, Zhang, Qingyuan, Chen, Yiding, Wang, Shouman, Wang, Xiaojia, Tong, Zhongsheng, Zhong, Yahua, Wang, Jiayu, Yan, Min, Yan, Xi, Wang, Chuan, Feng, Jifeng, Wang, Xiuli, Hu, Gang, Cheng, Ying, Ge, Ruimin, Zhu, Zhaoyin, Zhang, Wa, Shao, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883365/
https://www.ncbi.nlm.nih.gov/pubmed/36459284
http://dx.doi.org/10.1007/s10549-022-06785-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883365/
https://www.ncbi.nlm.nih.gov/pubmed/36459284
http://dx.doi.org/10.1007/s10549-022-06785-z

Ejemplares similares